Mesenchymal stem cells as carriers and amplifiers in CRAd delivery to tumors

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Xia, Xi ^a,b   Ji, Teng ^a   Chen, Pingbo ^a   Li, Xiao ^a,c   Fang, Yong ^a   Gao, Qinglei ^a   Liao, Shujie ^a   You, Lanying ^d   Xu, Hongbin ^a,e   Ma, Quanfu ^a   Wu, Peng ^a   Hu, Wencheng ^a   Wu, Mingfu ^a   Cao, Li ^a   Li, Kezhen ^a   Weng, Yanjie ^a   Han, Zhiqiang ^a   Wei, Junchen ^a   Liu, Ronghua ^a   Wang, Shixuan ^a   Xu, Gang ^a   Wang, Daowen ^a   Zhou, Jianfeng ^a   Ma, Ding ^a   more..

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b The 6th Affiliated Hospital of Shenzhen University Health Science Center   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

^d FUJIAN PROVINCIAL CANCER HOSPITAL   (China)

^e SHENZHEN PEOPLE'S HOSPITAL   (China)

Author keywords

Breast cancer; Cell carrier; Conditionally replicative adenovirus; Mesenchymal stem cell; Signal transducer and activator of transcription 3 (stat3)

Indexed keywords

CD11B ANTIGEN; COMPLEMENTARY DNA; CONDITIONALLY REPLICATING ADENOVIRUS; KI 67 ANTIGEN; RETINOBLASTOMA BINDING PROTEIN; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER SURVIVAL; CELL HOMING; CELL KILLING; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOLYSIS; DOWN REGULATION; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MELANOMA; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; TROPISM; TUMOR VOLUME; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION; ADENOVIRUS; ANIMAL; BREAST TUMOR; CELL SURVIVAL; COCULTURE; CYTOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; MESENCHYMAL STEM CELL TRANSPLANTATION; METABOLISM; NEOPLASM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ADENOVIRIDAE;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; COCULTURE TECHNIQUES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; KI-67 ANTIGEN; MELANOMA; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MICE; MICE, NUDE; NEOPLASMS; STAT3 TRANSCRIPTION FACTOR; VIRUS REPLICATION;

EID: 80155179342     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-134     Document Type: Article

References (47)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2007, 57:43-66. 10.3322/canjclin.57.1.43, 17237035.
2. Saad ED, Katz A, Buyse M. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol 2010, 28:1958-1962. 10.1200/JCO.2009.25.5414, 20194852.
3. Hartman M, Loy EY, Ku CS, Chia KS. Molecular epidemiology and its current clinical use in cancer management. Lancet Oncol 2010, 11:383-390. 10.1016/S1470-2045(10)70005-X, 20359664.
4. Komarova S, Kawakami Y, Stoff-Khalili MA, Curiel DT, Pereboeva L. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther 2006, 5:755-766. 10.1158/1535-7163.MCT-05-0334, 16546991.
5. Chiocca EA. Oncolytic viruses. Nat Rev Cancer 2002, 2:938-950. 10.1038/nrc948, 12459732.
6. Vile R, Ando D, Kirn D. The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider. Cancer Gene Ther 2002, 9:1062-1067. 10.1038/sj.cgt.7700548, 12522445.
7. Ries SJ, Brandts CH. Oncolytic viruses for the treatment of cancer: current strategies and clinical trials. Drug Discov Today 2004, 9:759-768. 10.1016/S1359-6446(04)03221-0, 15450242.
8. Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, Hawkins L, Kirn D. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000, 6:1134-1139. 10.1038/80474, 11017145.
9. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, Gore M, Ironside J, MacDougall RH, Heise C, Randlev B, Gillenwater AM, Bruso P, Kaye SB, Hong WK, Kirn DH. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000, 6:879-885. 10.1038/78638, 10932224.
10. Gao Q, Zhou J, Huang X, Chen G, Ye F, Lu Y, Li K, Zhuang L, Huang M, Xu G, Wang S, Ma D. Selective targeting of checkpoint kinase 1 in tumor cells with a novel potent oncolytic adenovirus. Mol Ther 2006, 13:928-937. 10.1016/j.ymthe.2005.12.009, 16459149.
11. Zhou J, Gao Q, Chen G, Huang X, Lu Y, Li K, Xie D, Zhuang L, Deng J, Ma D. Novel oncolytic adenovirus selectively targets tumor-associated polo-like kinase 1 and tumor cell viability. Clin Cancer Res 2005, 11:8431-8440. 10.1158/1078-0432.CCR-05-1085, 16322306.
12. Han Z, Hong Z, Chen C, Gao Q, Luo D, Fang Y, Cao Y, Zhu T, Jiang X, Ma Q, Li W, Han L, Wang D, Xu G, Wang S, Meng L, Zhou J, Ma D. A novel oncolytic adenovirus selectively silences the expression of tumor-associated Stat3 and exhibits potent antitumoral activity. Carcinogenesis 2009, 30:2014-2022. 10.1093/carcin/bgp249, 19843641.
13. Johnson M, Huyn S, Burton J, Sato M, Wu L. Differential biodistribution of adenoviral vector in vivo as monitored by bioluminescence imaging and quantitative polymerase chain reaction. Hum Gene Ther 2006, 17:1262-1269. 10.1089/hum.2006.17.1262, 17117891.
14. Tao N, Gao GP, Parr M, Johnston J, Baradet T, Wilson JM, Barsoum J, Fawell SE. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther 2001, 3:28-35. 10.1006/mthe.2000.0227, 11162308.
15. Martin K, Brie A, Saulnier P, Perricaudet M, Yeh P, Vigne E. Simultaneous CAR- and alpha V integrin-binding ablation fails to reduce Ad5 liver tropism. Mol Ther 2003, 8:485-494. 10.1016/S1525-0016(03)00182-5, 12946322.
16. Mathis JM, Stoff-Khalili MA, Curiel DT. Oncolytic adenoviruses-selective retargeting to tumor cells. Oncogene 2005, 24:7775-7791. 10.1038/sj.onc.1209044, 16299537.
17. Lang FF, Bruner JM, Fuller GN, Aldape K, Prados MD, Chang S, Berger MS, McDermott MW, Kunwar SM, Junck LR, Chandler W, Zwiebel JA, Kaplan RS, Yung WK. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 2003, 21:2508-2018. 10.1200/JCO.2003.11.138, 12839017.
18. Alemany R, Suzuki K, Curiel DT. Blood clearance rates of adenovirus type 5 in mice. J Gen Virol 2000, 81:2605-2609.
19. Kirn D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?. Gene Ther 2001, 8:89-98. 10.1038/sj.gt.3301377, 11313778.
20. Hamada K, Desaki J, Nakagawa K, Zhang T, Shirakawa T, Gotoh A, Tagawa M. Carrier cell-mediated delivery of a replication-competent adenovirus for cancer gene therapy. Mol Ther 2007, 15:1121-1128.
21. Kreppel F, Gackowski J, Schmidt E, Kochanek S. Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors. Mol Ther 2005, 12:107-117. 10.1016/j.ymthe.2005.03.006, 15963926.
22. Kühnel F, Schulte B, Wirth T, Woller N, Schäfers S, Zender L, Manns M, Kubicka S. Protein transduction domains fused to virus receptors improve cellular virus uptake and enhance oncolysis by tumor-specific replicating vectors. J Virol 2004, 78:13743-13754. 10.1128/JVI.78.24.13743-13754.2004, 533898, 15564483.
23. Glasgow JN, Everts M, Curiel DT. Transductional targeting of adenovirus vectors for gene therapy. Cancer Gene Ther 2006, 13:830-844. 10.1038/sj.cgt.7700928, 1781516, 16439993.
24. Serfozo P, Schlarman MS, Pierret C, Maria BL, Kirk MD. Selective migration of neuralized embryonic stem cells to stem cell factor and media conditioned by glioma cell lines. Cancer Cell Int 2006, 6:1. 10.1186/1475-2867-6-1, 1397869, 16436212.
25. Ziu M, Schmidt NO, Cargioli TG, Aboody KS, Black PM, Carroll RS. Glioma-produced extracellular matrix influences brain tumor tropism of human neural stem cells. J Neurooncol 2006, 79:125-133. 10.1007/s11060-006-9121-5, 16598423.
26. Sonabend AM, Ulasov IV, Tyler MA, Rivera AA, Mathis JM, Lesniak MS. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells 2008, 26:831-841. 10.1634/stemcells.2007-0758, 18192232.
27. Loebinger MR, Eddaoudi A, Davies D, Janes SM. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res 2009, 69:4134-4142. 2699841, 19435900.
28. Stoff-Khalili MA, Rivera AA, Mathis JM, Banerjee NS, Moon AS, Hess A, Rocconi RP, Numnum TM, Everts M, Chow LT, Douglas JT, Siegal GP, Zhu ZB, Bender HG, Dall P, Stoff A, Pereboeva L, Curiel DT. Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res Treat 2007, 105:157-167. 10.1007/s10549-006-9449-8, 17221158.
29. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008, 8:726-736. 10.1038/nri2395, 19172693.
30. Sasportas LS, Kasmieh R, Wakimoto H, Hingtgen S, van de Water JA, Mohapatra G, Figueiredo JL, Martuza RL, Weissleder R, Shah K. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci USA 2009, 106:822-827.
31. Karp JM, Leng Teo GS. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 2009, 4:206-216. 10.1016/j.stem.2009.02.001, 19265660.
32. Yong RL, Shinojima N, Fueyo J, Gumin J, Vecil GG, Marini FC, Bogler O, Andreeff M, Lang FF. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res 2009, 69:8932-8940. 10.1158/0008-5472.CAN-08-3873, 2789204, 19920199.
33. Magin AS, Körfer NR, Partenheimer H, Lange C, Zander A, Noll T. Primary cells as feeder cells for coculture expansion of human hematopoietic stem cells from umbilical cord blood--a comparative study. Stem Cells Dev 2009, 18:173-186. 10.1089/scd.2007.0273, 18471070.
34. Rae JM, Creighton CJ, Meck JM, Haddad BR, Johnson MD. MDA-MB-435 cells are derived from M14 melanoma cells--a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat 2007, 104:13-9. 10.1007/s10549-006-9392-8, 17004106.
35. Huang X, Bai X, Cao Y, Wu J, Huang M, Tang D, Tao S, Zhu T, Liu Y, Yang Y, Zhou X, Zhao Y, Wu M, Wei J, Wang D, Xu G, Wang S, Ma D, Zhou J. Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion. J Exp Med 2010, 207:505-520. 10.1084/jem.20090397, 2839144, 20176801.
36. Huang X, Zhuang L, Cao Y, Gao Q, Han Z, Tang D, Xing H, Wang W, Lu Y, Xu G, Wang S, Zhou J, Ma D. Biodistribution and kinetics of the novel selective oncolytic adenovirus M1 after systemic administration. Mol Cancer Ther 2008, 7:1624-1632. 10.1158/1535-7163.MCT-07-2134, 18566233.
37. Bianco P, Robey PG, Simmons PJ. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell 2008, 2:313-319. 10.1016/j.stem.2008.03.002, 2613570, 18397751.
38. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, Chen J, Hentschel S, Vecil G, Dembinski J, Andreeff M, Lang FF. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005, 65:3307-3318.
39. Knaän-Shanzer S, van de Watering MJ, van der Velde I, Gonçalves MA, Valerio D, de Vries AA. Endowing human adenovirus serotype 5 vectors with fiber domains of species B greatly enhances gene transfer into human mesenchymal stem cells. Stem Cells 2005, 23:1598-1607. 10.1634/stemcells.2005-0016, 16293583.
40. Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Rovira II, Nguyen AT, Malide D, Combs CA, Hall G, Zhang J, Raffeld M, Rogers TB, Stetler-Stevenson W, Frank JA, Reitz M, Finkel T. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med 2006, 203:1235-1247. 10.1084/jem.20051921, 2121206, 16636132.
41. Qiao L, Xu ZL, Zhao TJ, Ye LH, Zhang XD. Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling. Cancer Lett 2008, 269:67-77. 10.1016/j.canlet.2008.04.032, 18571836.
42. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449:557-563. 10.1038/nature06188, 17914389.
43. Burdelya L, Kujawski M, Niu G, Zhong B, Wang T, Zhang S, Kortylewski M, Shain K, Kay H, Djeu J, Dalton W, Pardoll D, Wei S, Yu H. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J Immunol 2005, 174:3925-31. 2632804, 15778348.
44. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, Dalton W, Jove R, Pardoll D, Yu H. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004, 10:48-54. 10.1038/nm976, 14702634.
45. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002, 196:254-65. 10.1002/path.1027, 11857487.
46. Piras F, Colombari R, Minerba L, Murtas D, Floris C, Maxia C, Corbu A, Perra MT, Sirigu P. The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase. Cancer 2005, 104:1246-54. 10.1002/cncr.21283, 16078259.
47. Fujiwara T, Fukushi J, Yamamoto S, Matsumoto Y, Setsu N, Oda Y, Yamada H, Okada S, Watari K, Ono M, Kuwano M, Kamura S, Iida K, Okada Y, Koga M, Iwamoto Y. Macrophage infiltration predicts a poor prognosis for human ewing sarcoma. Am J Pathol 2011, 179:1157-70. 10.1016/j.ajpath.2011.05.034, 21771572.